Global COVID-19 vaccine hesitancy among elderly: A systematic review

IF 2.7 Q3 IMMUNOLOGY

Vaccine: X Pub Date : 2024-11-15 DOI:10.1016/j.jvacx.2024.100584

M.C. Law , P.K.F. Chiu

{"title":"Global COVID-19 vaccine hesitancy among elderly: A systematic review","authors":"M.C. Law , P.K.F. Chiu","doi":"10.1016/j.jvacx.2024.100584","DOIUrl":null,"url":null,"abstract":"<div><h3>Background & Objectives</h3><div>Elderly infected with COVID-19 has high mortality risk, and the protection from COVID-19 vaccine is limited by vaccine hesitancy. The information of vaccine hesitancy in elderly is incomplete and fragmented. In this study, we attempt to examine the level of vaccine hesitancy in elderly and the related factors in global perspectives.</div></div><div><h3>Methods</h3><div>A systematic review was conducted to include observational studies of COVID-19 vaccine hesitancy in elderly from January 2020 to September 2021. Search strategies covering COVID-19 vaccine, vaccine hesitancy and elderly in four databases of PUBMED, MEDLINE, EMBASE and COCHRANE LIBRARY were adopted. Studies reporting COVID-19 vaccine hesitancy prevalence in elderly were included. A meta-analysis of the vaccine hesitancy prevalence was performed. The primary outcome is the vaccine hesitancy prevalence in elderly population globally. The secondary outcomes are the factors of COVID-19 vaccine hesitancy among elderly.</div></div><div><h3>Results</h3><div>Initial 479 articles were included for screening, with 54 studies included for meta-analysis of COVID-19 vaccine hesitancy in elderly and 6 studies included for qualitative analysis of factors for vaccine hesitancy. The overall prevalence of vaccine hesitancy was 27.7 % (95 % C.I: 23.8–31.6 %). The prevalence was significantly higher in Asia than in Europe (35.3 % VS 17.9 %, p < 0.05). The vaccine hesitancy was significantly higher before the launch of the vaccine than after (30.3 % VS 18.7 %, p < 0.05). Important factors of vaccine hesitancy in elderly identified were low income, low education, perception of COVID-19 being more contagious, more vaccine side effects and lower vaccine efficacy.</div></div><div><h3>Conclusions</h3><div>COVID-19 vaccine hesitancy is an important problem in elderly, with geographical variation. Tailored policy and strategies targeting the hesitancy factors were required to promote COVID-19 vaccine to elderly.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"21 ","pages":"Article 100584"},"PeriodicalIF":2.7000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine: X","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590136224001578","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background & Objectives

Elderly infected with COVID-19 has high mortality risk, and the protection from COVID-19 vaccine is limited by vaccine hesitancy. The information of vaccine hesitancy in elderly is incomplete and fragmented. In this study, we attempt to examine the level of vaccine hesitancy in elderly and the related factors in global perspectives.

Methods

A systematic review was conducted to include observational studies of COVID-19 vaccine hesitancy in elderly from January 2020 to September 2021. Search strategies covering COVID-19 vaccine, vaccine hesitancy and elderly in four databases of PUBMED, MEDLINE, EMBASE and COCHRANE LIBRARY were adopted. Studies reporting COVID-19 vaccine hesitancy prevalence in elderly were included. A meta-analysis of the vaccine hesitancy prevalence was performed. The primary outcome is the vaccine hesitancy prevalence in elderly population globally. The secondary outcomes are the factors of COVID-19 vaccine hesitancy among elderly.

Results

Initial 479 articles were included for screening, with 54 studies included for meta-analysis of COVID-19 vaccine hesitancy in elderly and 6 studies included for qualitative analysis of factors for vaccine hesitancy. The overall prevalence of vaccine hesitancy was 27.7 % (95 % C.I: 23.8–31.6 %). The prevalence was significantly higher in Asia than in Europe (35.3 % VS 17.9 %, p < 0.05). The vaccine hesitancy was significantly higher before the launch of the vaccine than after (30.3 % VS 18.7 %, p < 0.05). Important factors of vaccine hesitancy in elderly identified were low income, low education, perception of COVID-19 being more contagious, more vaccine side effects and lower vaccine efficacy.

Conclusions

COVID-19 vaccine hesitancy is an important problem in elderly, with geographical variation. Tailored policy and strategies targeting the hesitancy factors were required to promote COVID-19 vaccine to elderly.

查看原文本刊更多论文

全球老年人对 COVID-19 疫苗犹豫不决：系统回顾

背景& 目的感染 COVID-19 的老年人有很高的死亡风险，COVID-19 疫苗的保护作用因疫苗犹豫不决而受到限制。有关老年人疫苗接种犹豫不决的信息并不完整且零散。在本研究中，我们试图从全球视角考察老年人的疫苗犹豫水平及相关因素。方法对 2020 年 1 月至 2021 年 9 月期间有关老年人 COVID-19 疫苗犹豫的观察性研究进行系统回顾。在 PUBMED、MEDLINE、EMBASE 和 COCHRANE LIBRARY 四个数据库中采用涵盖 COVID-19 疫苗、疫苗迟疑和老年人的检索策略。纳入了报告老年人 COVID-19 疫苗接种犹豫率的研究。对疫苗犹豫接种率进行了荟萃分析。主要结果是全球老年人群的疫苗接种犹豫率。结果最初共纳入了 479 篇文章进行筛选，其中 54 项研究纳入了 COVID-19 疫苗在老年人群中犹豫不决的荟萃分析，6 项研究纳入了疫苗犹豫不决因素的定性分析。疫苗犹豫不决的总体流行率为 27.7%（95 % C.I：23.8-31.6%）。亚洲的发病率明显高于欧洲（35.3 % VS 17.9 %，p < 0.05）。疫苗上市前的犹豫率明显高于上市后（30.3 % VS 18.7 %，p < 0.05）。老年人对疫苗犹豫不决的重要因素包括低收入、低教育程度、认为 COVID-19 传染性更高、疫苗副作用更大以及疫苗效力较低。要向老年人推广 COVID-19 疫苗，需要针对犹豫因素制定有针对性的政策和策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊